Depression and Epilepsy: Comorbidity, Pathogenetic Similarity, and Principles of Treatment

Rider, Flora; Даниленко, О. А.; Grishkina, M. N.; Kustov, Georgii; Akzhigitov, R. G.; Лебедева, А. В.; Гехт, А Б

doi:10.1007/s11055-017-0534-8

Cited by 3 publications

(5 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its pathogenesis is very complex and it is often accompanied by depressive disorders (16). Epilepsy and depressive disorder are pathogenically similar and might be caused by reduced neurotransmitter release (17). The occurrence of epilepsy could promote the production of excitatory amino acids.…”

Section: Discussionmentioning

confidence: 99%

Comparison of clinical efficacy of oxcarbazepine and lamotrigine combined with escitalopram, and impact on prognostic quality of life in treating patients with epilepsy and depressive disorder

Zhang

Zhao

2020

Exp Ther Med

View full text Add to dashboard Cite

This study aimed to investigate the clinical efficacy of oxcarbazepine and lamotrigine combined with escitalopram in treating patients with epilepsy and depressive disorder, and their influence on the prognostic quality of life. A total of 108 patients with epilepsy and depression were selected as research participants. Among them, 53 patients were treated by oxcarbazepine combined with escitalopram (group A) and 55 patients were treated by lamotrigine combined with escitalopram (group B). Following six-month treatment, efficacy, epilepsy frequency and duration, Hamilton Depression Rating (HAMD) and Montgomery-Asberg Depression Rating (MADRS) scores, adverse reactions, improvement of electroencephalogram (EEG) epileptic discharge, quality of life, 1-year drug retention rate and withdrawal reasons of the two groups were compared. There was no remarkable difference in the total efficacy rate between both groups. The number and duration of epileptic seizures, improvement of EEG epileptic discharge and quality of life in the two groups significantly improved after treatment, with no marked difference. HAMD and MADRS scores of patients from group B were significantly lower after treatment compared with those of patients from group A. The incidence rate of adverse reactions in group B was dramatically lower compared with group A, and the 1-year drug retention rate of group B was dramatically higher compared with that in group A. Both oxcarbazepine and lamotrigine combined with escitalopram exhibited good efficacy in patients with epilepsy and depressive disorder, and they may effectively improve the prognostic quality of life of patients. Lamotrigine combined with escitalopram presented with a better antidepressant effect and safety, with higher patient tolerance.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of clinical efficacy of oxcarbazepine and lamotrigine combined with escitalopram, and impact on prognostic quality of life in treating patients with epilepsy and depressive disorder

Zhang

Zhao

2020

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Several causative mechanisms linking epilepsy and depression have been proposed, including a decrease in function of specific neurotransmitters (serotonin, noradrenaline, dopamine and GABA), tissue atrophy, morphological alterations in limbic areas and higher cytokine concentrations (IL-1beta) ( Kanner, 2016 ; Rider et al , 2018 ). Comorbidities represent an important issue also for the healthcare system because they require additional, expensive medical interventions and can also aggravate the severity of epilepsy or the side effects of anti-epileptic drugs.…”

Section: Introductionmentioning

confidence: 99%

Implication of sestrin3 in epilepsy and its comorbidities

Lovisari

Roncon

Soukoupova

et al. 2020

Brain Communications

View full text Add to dashboard Cite

Epilepsy is a serious neurological disorder affecting about 1% of the population worldwide. Epilepsy may arise as a result of acquired brain injury, or as a consequence of genetic predisposition. To date, genome-wide association studies and exome sequencing approaches have provided limited insights into the mechanisms of acquired brain injury. We have previously reported a pro-epileptic gene network, which is conserved across species, encoding inflammatory processes and positively regulated by sestrin 3 (SESN3). In this study, we investigated the phenotype of SESN3 knock-out rats in terms of susceptibility to seizures and observed a significant delay in status epilepticus onset in SESN3 knock-out compared to control rats. This finding confirms previous in vitro and in vivo evidence indicating that SESN3 may favor occurrence and/or severity of seizures. We also analyzed the phenotype of SESN3 knock-out rats for common comorbidities of epilepsy, i.e. anxiety, depression, and cognitive impairment. SESN3 knock-out rats proved less anxious compared to control rats in a selection of behavioral tests. Taken together, the present results suggest that SESN3 may regulate mechanisms involved in the pathogenesis of epilepsy and its comorbidities.

show abstract

“…In the IDD group, the history of affective disorders was significantly longer (4 [1][2][3][4][5][6][7][8][9] vs. 2 [1][2][3][4][5], p = .001), with significantly higher scores on all psychometric scales (see Figure 2). Weak to moderate correlation of the total scores of IDDI subscales with BDI (r = .13, p = .14) and BAI (r = .42, p < .001) was found.…”

Section: Idd and Affective Disordersmentioning

confidence: 99%

“…2 In PWE, affective disorders are associated with a more severe course of epilepsy and worse outcome, and depression has a significant impact on quality of life. [3][4][5][6] Depression and epilepsy have common pathogenetic mechanisms; this may be one of the reasons for their high level of comorbidity. 7 Moreover, epidemiological studies show that not only is epilepsy a risk factor for depression, but the affective disorder itself significantly increases the risk of new onset epilepsy.…”

Section: Introductionmentioning

confidence: 99%

“…The prevalence of a history of depression in patients with epilepsy (PWE) is 21.9% (95% confidence interval [CI] = 20.8%–23.0%), 1 and the risk of current depression is 2.77 (95% CI = 2.09–3.67)‐fold increased when compared to current depression in the general population 2 . In PWE, affective disorders are associated with a more severe course of epilepsy and worse outcome, and depression has a significant impact on quality of life 3–6 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Interictal dysphoric disorder in people with and without epilepsy

et al. 2021

View full text Add to dashboard Cite

Interictal dysphoric disorder (IDD) has been regarded as an affective disorder occurring only in people with epilepsy (PWE). Data showing similar characteristics and similar prevalence of IDD in patients with migraine and with psychogenic nonepileptic seizures question the epilepsy-specific nature of IDD. The aim of the study was to investigate the nature of IDD in people with prevalent epilepsy with mood disorders and people with mood disorders who are free of neurological disease. Methods: This is a case-control study, with 142 patients with a confirmed diagnosis of epilepsy and major depressive disorder (MDD; cases) and 222 patients with MDD only (controls). MDD diagnosis was confirmed by a structured clinical interview for Diagnostic and Statistical Manual of Mental Disorders, 4th edition (SCID-I-RV). We used the Beck Depression Inventory and the Beck Anxiety Inventory to estimate anxiety and depression levels and the Interictal Dysphoric Disorder Inventory (IDDI) to confirm the presence of IDD. Mann-Whitney U test, Pearson chi-squared, Spearman correlation, and logistic regression were used.Results: No differences were found in the prevalence of IDD between PWE with MDD and people with MDD alone (88.73% vs. 85.13%, χ2 = .96, p = .32). There were no differences between the groups overall or for any IDDI subscales (all p > .05). In both groups, IDD symptoms were grouped with the same incidence and had the same duration and periodicity. IDD was not associated with epilepsy (odds ratio = .84, 95% confidence interval = .40-1.98, p = .72). No significant correlation was found between epilepsy, demographic characteristics, and all IDDI subscales (all p > .05).Notably, patients with IDD suffered from affective disorders longer (6.68 ± 6.82 years vs. 3.7 ± 3.97 years, p = .001) and also received higher scores on all psychometric scales (all p < .05). Significance: This study does not confirm the specificity of IDD for epilepsy. The presence of IDD symptoms may be associated with a more severe course of MDD and significant anxiety distress.

show abstract

Depression and Epilepsy: Comorbidity, Pathogenetic Similarity, and Principles of Treatment

Cited by 3 publications

References 50 publications

Comparison of clinical efficacy of oxcarbazepine and lamotrigine combined with escitalopram, and impact on prognostic quality of life in treating patients with epilepsy and depressive disorder

Comparison of clinical efficacy of oxcarbazepine and lamotrigine combined with escitalopram, and impact on prognostic quality of life in treating patients with epilepsy and depressive disorder

Implication of sestrin3 in epilepsy and its comorbidities

Interictal dysphoric disorder in people with and without epilepsy

Contact Info

Product

Resources

About